Iterion Therapeutics

Iterion Therapeutics is a clinical-stage biopharmaceutical company headquartered in Houston, Texas, dedicated to developing novel therapeutics for cancer. The company's lead product, tegavivint, is a first-in-class small molecule that shuts down oncogenic Wnt/β-catenin signaling by selectively degrading nuclear β-catenin. Iterion positions tegavivint as the most advanced Wnt/β-catenin inhibitor in development, with potential applicability across more than 500,000 cancers annually. The company's primary clinical focus is advanced hepatocellular carcinoma (HCC), where approximately 40% of patients harbor Wnt/β-catenin mutations and no targeted therapies currently exist. In a Phase 1 study, tegavivint achieved partial responses and durable disease control in heavily pre-treated, Wnt-mutated HCC patients, supported by ctDNA reductions and improvements in liver function. Iterion reports that tegavivint has demonstrated strong safety, excellent tolerability, and outcomes superior to late-line TKIs, positioning it to become the first targeted therapy for Wnt-mutated HCC. Beyond HCC, Iterion is advancing expansion opportunities into other Wnt-driven tumors including colorectal cancer (CRC), representing a multi-billion-dollar market. Iterion's scientific approach centers on direct targeting of the β-catenin transcriptional complex. Dysregulated Wnt/β-catenin signaling is involved in several hallmarks of cancer, but key pathway members—including β-catenin—have historically been resistant to conventional drug development or plagued with off-target toxicities. Tegavivint binds to Transducin β-like Protein 1 (TBL1), a newly characterized target in the Wnt/β-catenin pathway, disrupting the interaction between β-catenin and TBL1, promoting degradation of nuclear β-catenin, and preventing transcription of Wnt/β-catenin targeted oncogenes. Preclinical studies have shown tegavivint inhibits β-catenin activity without overt toxicity and is not affected by CTNNB1 gain-of-function mutations typically found in cancer cells. In parallel, Iterion has ongoing R&D programs investigating second-generation TBL1 inhibitors. The company also maintains deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials, including a study with HonorHealth. Iterion Therapeutics operates as a private company and is not listed on any public stock exchange.

Iterion Therapeutics is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing novel therapeutics for cancer. The company's lead program centers on tegavivint (also known as BC2059), a first-in-class small molecule designed to inhibit the Wnt/β-catenin signaling pathway by targeting Transducin β-like Protein 1 (TBL1). The scientific foundation of Iterion's approach rests on the recognition that dysregulated Wnt/β-catenin signaling is involved in several hallmarks of cancer, yet key pathway members—including β-catenin—have historically been resistant to conventional drug development or associated with off-target toxicities. TBL1 was identified as a newly characterized target in the pathway that binds to accumulated nuclear β-catenin, forming an active transcription complex that prevents nuclear degradation of β-catenin and activates genes necessary for oncogenic activity. Tegavivint binds to TBL1 and disrupts the β-catenin–TBL1 interaction, promoting degradation of nuclear β-catenin and preventing transcription of Wnt/β-catenin targeted oncogenes. Preclinical studies have shown that tegavivint inhibits β-catenin activity without overt toxicity and is not affected by CTNNB1 gain-of-function mutations typically found in cancer cells. Iterion has stated that tegavivint is the most advanced Wnt/β-catenin inhibitor in development, with broad applicability across more than 500,000 cancers annually. Iterion's primary clinical focus is advanced hepatocellular carcinoma (HCC), where approximately 40% of patients harbor Wnt/β-catenin mutations and no targeted therapies exist. In a Phase 1 study, tegavivint achieved partial responses and durable disease control in heavily pre-treated, Wnt-mutated HCC patients, supported by ctDNA reductions and improvements in liver function. The company reports strong safety, excellent tolerability, and outcomes superior to late-line TKIs, positioning tegavivint to potentially become the first targeted therapy for Wnt-mutated HCC. Beyond HCC, Iterion is advancing expansion opportunities into other Wnt-driven tumors including colorectal cancer (CRC). In parallel with the tegavivint program, Iterion has ongoing R&D programs investigating and developing second-generation TBL1 inhibitors. The company also maintains deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials, including a study with HonorHealth. Iterion Therapeutics operates as a private company and is not listed on any public stock exchange.

Clinical-stage biopharmaceutical company developing first-in-class TBL1 inhibitors to target Wnt/β-catenin-driven cancers, with tegavivint positioned as the most advanced Wnt/β-catenin inhibitor in development.

• Tegavivint (BC2059)

  A first-in-class small molecule that shuts down oncogenic Wnt/β-catenin signaling by selectively degrading nuclear β-catenin. It targets TBL1, a necessary co-activator for Wnt-activated gene transcription, thereby blocking β-catenin's oncogenic activity while avoiding the toxicities that have limited upstream Wnt inhibitors.

• Second-generation TBL1 inhibitors

  Preclinical R&D programs investigating and developing next-generation TBL1 inhibitors.

1. 1Home - Iterion Therapeuticsiteriontherapeutics.com
2. 2Our Science - Iterion Therapeuticsiteriontherapeutics.com
3. 3Iterion Therapeutics (United States) - Wikidatawikidata.org